Key Metrics
6.5
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
1.15
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Indexed in the following public directories
-
Web of Science -
Scopus -
DOAJ -
SJR
Journal Specifications
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2008 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 16 |
| Article Processing Charges | USD 2390 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
Planning to publish in Lung Cancer: Targets and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
- 1 Dec 24
- Lung Cancer: Targets and Therapy
-
Full paper
Adagrasib in KRYSTAL-12has Broken the KRAS G12C Enigma Code in Non-Small Cell Lung Carcinoma.
- 1 Oct 24
- Lung Cancer (Auckland, N.Z.)
-
Full paper
NRG1 Fusions in NSCLC: Being eNRGy Conscious.
- 1 Oct 24
- Lung Cancer (Auckland, N.Z.)
-
Full paper
Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea.
- 1 Oct 24
- Lung Cancer (Auckland, N.Z.)
-
Full paper
Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK-Positive Non-Small Cell Lung Cancer.
- 1 Aug 24
- Lung Cancer (Auckland, N.Z.)
-
Full paper
Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.
- 1 Aug 24
- Lung Cancer (Auckland, N.Z.)
Scite analysis
Powered by scite_
188 articles received 2.2k citations see all
- 84 Supporting
- 2,057 Mentioning
- 14 Contrasting
Editorial notices
- 0 Retractions
- 0 Withdrawals
- 0 Corrections
- 0 Errata
- 0 Expression of Concern
FAQs
How long has Lung Cancer: Targets and Therapy been actively publishing?
Lung Cancer: Targets and Therapy has been in operation since 2008 till date.
What is the publishing frequency of Lung Cancer: Targets and Therapy ?
Lung Cancer: Targets and Therapy published with a Continuous publication frequency.
How many articles did Lung Cancer: Targets and Therapy publish last years ?
In 2024, Lung Cancer: Targets and Therapy published 19 articles.
What is the eISSN & pISSN for Lung Cancer: Targets and Therapy ?
For Lung Cancer: Targets and Therapy,eISSN is 1179-2728 and pISSN is1179-2728.
What is Citescore for Lung Cancer: Targets and Therapy ?
Citescore for Lung Cancer: Targets and Therapy is 6.5.
What is SNIP score for Lung Cancer: Targets and Therapy ?
SNIP score for Lung Cancer: Targets and Therapy is 1.15.
Who is the publisher of Lung Cancer: Targets and Therapy ?
DOVE MEDICAL PRESS LTD is the publisher of Lung Cancer: Targets and Therapy.